Hormonal therapy might be a better choice as maintenance treatment than capecitabine after response to first-line capecitabine-based combination chemotherapy for patients with hormone receptor-positive and HER2-negative, metastatic breast cancer.
CONCLUSION: For HR-positive and HER2-negative MBC patients, HT might be considered a treatment after response to FCCT but prior to MCT as a long-term administration.
PMID: 27112139 [PubMed - in process]
Source: Chinese Journal of Cancer - Category: Cancer & Oncology Tags: Chin J Cancer Source Type: research
More News: Academies | Breast Cancer | Cancer | Cancer & Oncology | Chemotherapy | Clinical Trials | Hematology | HER2 | Hormonal Therapy | Hormones | Men | Menopause | Xeloda